Skip to Main Content

Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

Conditions

Diseases of the Respiratory Systems

Phase III

What is the purpose of this trial?

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

  • Trial with
    FibroGen, Inc.
  • Start Date
    11/20/2020
  • End Date
    03/31/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/17/2021
  • Study HIC
    #2000028820